Abstract
BackgroundTo evaluate the expression of EGFR and COX-2 and their correlation with prognosis in NSCLCMethodsThe paraffin embedded tumor samples of 50 NSCLC patients receiving radical resection were analyzed immunohistochemically for EGFR and COX-2 expression and their prognostic values were explored.ResultsThe positive rate of EGFR protein in NSCLC tumor cells was 46%, which was significantly higher than its expression in normal lung (p = 0.0234) and paracancerous tissues (p = 0.020). EGFR expression was significantly higher in nodal positive than in nodal negative patients (p = 0.04). The mean survival time for EGFR positive patients (31 months) was significantly lower than that for patients with EGFR negative expression (48 months) (p = 0.008,). In patients receiving post-operation thoracic irradiation, the mean survival time for EGFR positive patients was significantly lower than that for patients without EGFR positive expression (25 vs. 48 months, P = 0.004). The positive rate of COX-2 protein expression in NSCLC tumor cells was 90%, which was significantly higher than that in normal tissue(p = 0.00) and paracancerous tissue (p = 0.00). There was no correlation between COX-2 expression and patient survival, and no correlation between COX-2 and EGFR protein expression (P = 0.555).ConclusionsCOX-2 and EGFR are over-expressed in NSCLC. EGFR is an independent prognostic factor and a predictive factor for radiotherapy response in NSCLC.
Highlights
To evaluate the expression of epidermal growth factor receptor (EGFR) and COX-2 and their correlation with prognosis in non-small cell lung cancer (NSCLC)
EGFR protein expression The positive rate of EGFR protein in NSCLC tumor cells were 46%, which was significantly higher than its expression in normal lung (p = 0.0234) and paracancerous (p = 0.020)(Figures 1A &1B, Tables 1 &2)
There is no significant difference between age (60 vs. under 60 ys), gender, adenovs. non-adenocarcinoma, the differentiation of tumor, and staging
Summary
To evaluate the expression of EGFR and COX-2 and their correlation with prognosis in NSCLC. With advances in cytogenetic and molecular biology, the detection and analysis of tumor suppressor gene and oncogene may provide predictive values for prognosis and treatment choice for NSCLC. Among these molecular markers, the epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) over expression are common in NSCLC [2,3,4,5,6,7,8,9]. Deregulation of receptor tyrosine kinases as a result of overexpression or activating mutations leads to the promotion of cell proliferation or migration, inhibition of cell death, or the induction of angiogenesis [13,14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Experimental & Clinical Cancer Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
